Anthony G. Viscogliosi, Chairman & CEO of SBi, said: “August was our best month ever in North America for S.T.A.R. surgeries. This performance is very encouraging for a number of reasons. First, August is historically the slowest month of the year for surgeries. The global economic slowdown has had a dampening effect on the volume of elective procedures for virtually all orthopedic companies. In spite of these hurdles, the number of S.T.A.R. implantations in August was 40% more than in July.”
Two of the nation’s best known foot & ankle surgeons who took the lead in both the clinical trial that led to FDA’s Approval Order and surgeon training for S.T.A.R., Roger A. Mann1, MD and James A. Nunley2, MD explained why the implant has been so rapidly accepted in the US.
“A distinct advantage for the S.T.A.R. ankle has been the successful results of the clinical trial that prompted the FDA to conclude that the procedure is safe, effective and superior to fusion in selected patients,” Dr. Nunley noted.
He added: “On the advice of their physician, patients who may have postponed ankle surgery now understand why S.T.A.R. is the leading total ankle replacement system due to its precise guidance instrumentation and compelling clinical history. Only through the clinical trials were we able to prove that the time had come to change the paradigm from fusion to arthroplasty.”
Dr. Mann added: “Like any innovative technology, most surgeons and patients like to wait and see. I have been an advocate and educator in the S.T.A.R. procedure for more than a decade and the survivability of the implant has proven to be excellent in 90% of my patients. This coupled with S.T.A.R.’s superiority in efficacy versus fusion will lead to further positively transforming the quality of life for tens of thousands of patients that previously had only fusion as a way to treat late-stage ankle arthritis.”
Mr. Viscogliosi added: “The one-on-one training sessions conducted with foot & ankle surgeons over the last several months, along with the new instrumentation that has been developed, have contributed to S.T.A.R.’s increasing success.”
Of the approximately 390,000 patients in the US diagnosed annually with ankle arthritis, SBi believes that as many as 70,000 of them could benefit from the S.T.A.R. implant. The company also believes it is well positioned to take full advantage of a vastly underserved market and, more importantly, enable surgeons to advance the standard of patient care.
The S.T.A.R. total ankle replacement system, that received pre-market approval (PMA) from the FDA on May 27, 2009, is indicated for replacement of painful arthritic ankle joints affected by osteoarthritis, post-traumatic arthritis or rheumatoid arthritis.
The S.T.A.R. is the only three-piece, cementless, mobile-bearing, total ankle replacement system to have received PMA approval from the FDA and the only PMA-approved total ankle replacement commercially available in the US. Its titanium plasma spray coating allows for better bone in-growth, stabilization and bone preservation.
SBi has been attracting considerable attention in recent months in both the financial and the orthopedics sector. Out of nearly 5,200 companies considered, SBi was the only orthopedic company on the list of the top 50 U.S. VC-backed companies in the Wall Street Journal article “Sizing Up Promising Young Firms” on March 9, 2010. Additionally, SBi was the 7th highest-ranked health care company and was 24th among the 50 companies highlighted.
SBi closed on $12 million in Series E funding from Olympus Corporation in March 2010. The company secured a $30mm debt facility from Fortress Investment Group to fund accelerated business expansion and refinance existing indebtedness in November 2009. In mid-2009 SBi closed on $144 million in Series D and Series C funding from a host of investors including, Goldman, Sachs & Co., Khazanah Nasional Berhad (the investment firm of the Government of Malaysia), Malaysian Technology Development Corporation (MTDC), an integrated Malaysian-based venture capital company, The Family Office of Bahrain, Viscogliosi Brothers, LLC, Trevi Health Ventures, NGN Capital, 3i Group, and TGap Ventures, among others.
1, 2 Drs. Roger A. Mann and James A. Nunley are consultants to SBi and investigators in the S.T.A.R. Post-Approval study.
About Small Bone Innovations, Inc.
Small Bone Innovations, Inc. (SBi) was founded in 2004 by Viscogliosi Brothers, LLC (VB), a New York-based merchant banking firm that specializes in the musculoskeletal/orthopedics sector. VB created SBi as the first company to focus purely on small bones & joints. By integrating established companies and professionals in the field, SBi offers a broad, clinically proven portfolio of products and technologies to treat trauma and diseases in small bones & joints. Today, SBi has facilities in New York, NY, Morrisville, PA, Bourg-en-Bresse, France, Donaueschingen, Germany, and Kuala Lumpur, Malaysia and has sold its products in 46 countries.
For more information on SBi, please visit: www.totalsmallbone.com
This news release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting SBi’s business including increased competition; the ability of SBi to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks.